SCHEMBL22816293

SCHEMBL22816293

O=C(O)c1[nH]nnc1-c1ccc(-c2ccc(Cl)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HAO1 Q9UJM8 3/20 0.48
CA12 O43570 1/20 0.47
ALPL P05186 1/20 0.47
NOTUM Q6P988 1/20 0.46
MAP2K4 P45985 1/20 0.46
CTRC Q99895 2/20 0.43
CDH1 P12830 1/20 0.42
APC P25054 1/20 0.42
CTNNB1 P35222 1/20 0.42
TCF7L2 Q9NQB0 1/20 0.42
GPR35 Q9HC97 1/20 0.39
ALAD P13716 1/20 0.39
MAPK14 Q16539 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
CHEK2 O96017 1/20 0.38
MARS1 P56192 1/20 0.38
SIRT1 Q96EB6 1/20 0.37
KMO O15229 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23294603 0.98 HAO1 (0.49) HAO1CA12ALPLNOTUMMAP2K4
SCHEMBL23328966 0.91 MAP2K4 (0.41) HAO1CA12ALPLMAP2K4
Trifluoroacetic Acid SCHEMBL22608389 0.91 HAO1 (0.42) HAO1CA12ALPLNOTUMMAP2K4
SCHEMBL22608528 0.90 HAO1 (0.59) HAO1CA12ALPLCDH1CTNNB1
SCHEMBL29852028 0.87 MAP2K4 (0.45) HAO1CA12ALPLNOTUMMAP2K4
SCHEMBL23294619 0.87 MAP2K4 (0.45) HAO1CA12ALPLNOTUMMAP2K4
SCHEMBL23294477 0.86 MAP2K4 (0.45) HAO1ALPLMAP2K4
SCHEMBL23294375 0.86 MAP2K4 (0.45) HAO1ALPLMAP2K4
SCHEMBL23294377 0.85 HAO1 (0.46) HAO1MAP2K4CTRCGPR35KMO
SCHEMBL23294638 0.84 KMO (0.48) HAO1MAP2K4TSHRKMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4051667-B1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS LILAC THERAPEUTICS INC (US) 2026-01-28 EP disclosed
CN-114929676-B Heterocyclic carboxylate compounds as glycolate oxidase inhibitors 紫丁香疗法有限公司 2025-04-29 CN disclosed
US-20250064787-A1 Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors LILAC THERAPEUTICS INC (US) 2025-02-27 US disclosed
EP-4470538-A2 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. (US) 2024-12-04 EP disclosed
CN-117126151-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-28 CN disclosed
CN-117069712-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-17 CN disclosed
CN-117069713-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-17 CN disclosed
CN-117024420-A Glycolate oxidase inhibitors for use in the treatment of disease 生物马林药物股份有限公司 2023-11-10 CN disclosed
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 US disclosed
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 US disclosed
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors Lilac Therapeutics, Inc. (US) 2023-11-07 US disclosed
EP-4051667-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. (US) 2022-09-07 EP disclosed
CN-114929676-A Heterocyclic carboxylate compounds as glycolate oxidase inhibitors 紫丁香疗法有限公司 2022-08-19 CN disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 US disclosed
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2021-06-10 US disclosed
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. 2021-05-06 US disclosed
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS Lilac Therapeutics, Inc. 2021-05-06 US disclosed
WO-2021086874-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS GyanRx Sciences, Inc. (US) 2021-05-06 WO disclosed
WO-2020257487-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2020-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11806335-B2 Heterocyclic carboxylate compounds as glycolate oxidase inhibitors UGDH, PGD, PNPO HAO1 46/4885CA12 812/4885ALPL 1290/4885
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT HAO1 9/4885CA12 1470/4885ALPL 728/4885
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT HAO1 9/4885CA12 1470/4885ALPL 728/4885
US-20210128532-A1 HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS UGDH, PGD, PNPO HAO1 46/4885CA12 812/4885ALPL 1290/4885
US-20250064787-A1 Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors GLS, DUOX1, HAO1 HAO1 3/4885CA12 1202/4885ALPL 2290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.